MAD1L1 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:8379, HGNC:6762, MAD1, MAD1L1, MIM:602686, NM_001013836, NM_001013837, NM_001304523, NM_001304524, NM_001304525, NM_003550, NP_001013858, NP_001013859, NP_001291452, NP_001291453, NP_001291454, NP_003541, PIG9, TP53I9, TXBP181, mitotic arrest deficient 1 like 1

Omim:OMIM:602686

Id:ENSG00000002822

Hgnc:HGNC:6762

Entrez:8379

Ensembl:ENSG00000002822

Description:mitotic arrest deficient 1 like 1

MAD1L1 is a component of the mitotic spindle-assembly checkpoint that prevents the onset of anaphase until all chromosome are properly aligned at the metaphase plate. MAD1L1 functions as a homodimer and interacts with MAD2L1. MAD1L1 may play a role in cell cycle control and tumor suppression. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2015]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View MAD1L1's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with MAD1L1.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using MAD1L1.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for MAD1L1.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with MAD1L1.

Results found

Linked to

	Label	Description
	GSE193351 ruxolitinib 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 6 V 10 CRIZOTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE228430 FABP5 inhibition Huh-7 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 6 V 5 CRIZOTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE193993 SSTR2 knockout 5 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE125782 3 V 1 GLUTAMINE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 3 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE67266 7 V 3 ETOPOSIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE216540 1 V 6 FULVESTRANT HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE185519 3 V 0 GILTERITINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

GSE193351 ruxolitinib 1 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 6 V 10 CRIZOTINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE228430 FABP5 inhibition Huh-7 2 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 6 V 5 CRIZOTINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE193993 SSTR2 knockout 5 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE125782 3 V 1 GLUTAMINE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 3 v 7 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE67266 7 V 3 ETOPOSIDE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE216540 1 V 6 FULVESTRANT HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE185519 3 V 0 GILTERITINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.